DIH Holding US, Inc.
Get $10 bonus on your first $100 deposit for DHAI
Get $10 bonus on your first $100 deposit for DHAI
DIH Holding US, Inc. (DHAI) Stock Competitors & Peer Comparison
See (DHAI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DHAI | $0.00 | -90.00% | 2.1K | N/A | -$0.24 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $95.07 | -1.80% | 166.9B | 26.90 | $3.57 | +1.32% |
| SYK | $338.24 | -1.48% | 129.6B | 40.23 | $8.41 | +1.02% |
| MDT | $84.79 | -1.62% | 109.1B | 23.74 | $3.58 | +1.66% |
| BSX | $61.58 | -4.13% | 90.6B | 31.44 | $1.94 | N/A |
| BRKRP | $327.56 | +2.83% | 48.8B | N/A | N/A | +0.24% |
| EW | $81.34 | +0.43% | 47.3B | 45.00 | $1.81 | N/A |
| PHG | $28.85 | -2.88% | 28B | 26.54 | $1.10 | +3.32% |
| DXCM | $63.85 | -0.20% | 25.2B | 30.92 | $2.09 | N/A |
Stock Comparison
DHAI vs BSX-PA Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DHAI is priced at $0.00, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DHAI's ROE is +0.22%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSX-PA's competition here
DHAI vs ABT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ABT has a market cap of 166.9B. Regarding current trading prices, DHAI is priced at $0.00, while ABT trades at $95.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 26.90. In terms of profitability, DHAI's ROE is +0.22%, compared to ABT's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ABT's competition here
DHAI vs SYK Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SYK has a market cap of 129.6B. Regarding current trading prices, DHAI is priced at $0.00, while SYK trades at $338.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 40.23. In terms of profitability, DHAI's ROE is +0.22%, compared to SYK's ROE of +0.15%. Regarding short-term risk, DHAI is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SYK's competition here
DHAI vs MDT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, MDT has a market cap of 109.1B. Regarding current trading prices, DHAI is priced at $0.00, while MDT trades at $84.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 23.74. In terms of profitability, DHAI's ROE is +0.22%, compared to MDT's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MDT's competition here
DHAI vs BSX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BSX has a market cap of 90.6B. Regarding current trading prices, DHAI is priced at $0.00, while BSX trades at $61.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 31.44. In terms of profitability, DHAI's ROE is +0.22%, compared to BSX's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSX's competition here
DHAI vs BRKRP Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BRKRP has a market cap of 48.8B. Regarding current trading prices, DHAI is priced at $0.00, while BRKRP trades at $327.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is N/A. In terms of profitability, DHAI's ROE is +0.22%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, DHAI is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BRKRP's competition here
DHAI vs EW Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, EW has a market cap of 47.3B. Regarding current trading prices, DHAI is priced at $0.00, while EW trades at $81.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas EW's P/E ratio is 45.00. In terms of profitability, DHAI's ROE is +0.22%, compared to EW's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EW's competition here
DHAI vs PHG Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PHG has a market cap of 28B. Regarding current trading prices, DHAI is priced at $0.00, while PHG trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 26.54. In terms of profitability, DHAI's ROE is +0.22%, compared to PHG's ROE of +0.08%. Regarding short-term risk, DHAI is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PHG's competition here
DHAI vs DXCM Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, DXCM has a market cap of 25.2B. Regarding current trading prices, DHAI is priced at $0.00, while DXCM trades at $63.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 30.92. In terms of profitability, DHAI's ROE is +0.22%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, DHAI is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check DXCM's competition here
DHAI vs STE Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, STE has a market cap of 22.2B. Regarding current trading prices, DHAI is priced at $0.00, while STE trades at $226.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas STE's P/E ratio is 31.57. In terms of profitability, DHAI's ROE is +0.22%, compared to STE's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check STE's competition here
DHAI vs ZBH Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, DHAI is priced at $0.00, while ZBH trades at $95.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 26.90. In terms of profitability, DHAI's ROE is +0.22%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, DHAI is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ZBH's competition here
DHAI vs ABMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DHAI is priced at $0.00, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DHAI's ROE is +0.22%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ABMD's competition here
DHAI vs SNN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SNN has a market cap of 14.6B. Regarding current trading prices, DHAI is priced at $0.00, while SNN trades at $33.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 23.92. In terms of profitability, DHAI's ROE is +0.22%, compared to SNN's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SNN's competition here
DHAI vs PODD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PODD has a market cap of 14.1B. Regarding current trading prices, DHAI is priced at $0.00, while PODD trades at $198.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 57.72. In terms of profitability, DHAI's ROE is +0.22%, compared to PODD's ROE of +0.17%. Regarding short-term risk, DHAI is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PODD's competition here
DHAI vs ALGN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ALGN has a market cap of 13.7B. Regarding current trading prices, DHAI is priced at $0.00, while ALGN trades at $199.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 33.92. In terms of profitability, DHAI's ROE is +0.22%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, DHAI is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ALGN's competition here
DHAI vs GMED Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, GMED has a market cap of 13.1B. Regarding current trading prices, DHAI is priced at $0.00, while GMED trades at $95.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 24.69. In terms of profitability, DHAI's ROE is +0.22%, compared to GMED's ROE of +0.12%. Regarding short-term risk, DHAI is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check GMED's competition here
DHAI vs PEN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, DHAI is priced at $0.00, while PEN trades at $329.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 72.97. In terms of profitability, DHAI's ROE is +0.22%, compared to PEN's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PEN's competition here
DHAI vs SWAV Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DHAI is priced at $0.00, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DHAI's ROE is +0.22%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, DHAI is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SWAV's competition here
DHAI vs BIO Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, DHAI is priced at $0.00, while BIO trades at $310.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 10.89. In terms of profitability, DHAI's ROE is +0.22%, compared to BIO's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BIO's competition here
DHAI vs BIO-B Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, DHAI is priced at $0.00, while BIO-B trades at $303.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is 10.89. In terms of profitability, DHAI's ROE is +0.22%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BIO-B's competition here
DHAI vs GKOS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, GKOS has a market cap of 7.2B. Regarding current trading prices, DHAI is priced at $0.00, while GKOS trades at $123.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -37.98. In terms of profitability, DHAI's ROE is +0.22%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, DHAI is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check GKOS's competition here
DHAI vs BRKR Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BRKR has a market cap of 6.3B. Regarding current trading prices, DHAI is priced at $0.00, while BRKR trades at $41.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is -274.00. In terms of profitability, DHAI's ROE is +0.22%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, DHAI is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BRKR's competition here
DHAI vs NARI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DHAI is priced at $0.00, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, DHAI's ROE is +0.22%, compared to NARI's ROE of -0.00%. Regarding short-term risk, DHAI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NARI's competition here
DHAI vs IRTC Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, DHAI is priced at $0.00, while IRTC trades at $123.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -88.60. In terms of profitability, DHAI's ROE is +0.22%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, DHAI is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IRTC's competition here
DHAI vs TMDX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, DHAI is priced at $0.00, while TMDX trades at $112.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 23.23. In terms of profitability, DHAI's ROE is +0.22%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, DHAI is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TMDX's competition here
DHAI vs AXNX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DHAI is priced at $0.00, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DHAI's ROE is +0.22%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DHAI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AXNX's competition here
DHAI vs LIVN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, LIVN has a market cap of 3.6B. Regarding current trading prices, DHAI is priced at $0.00, while LIVN trades at $66.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is -14.79. In terms of profitability, DHAI's ROE is +0.22%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, DHAI is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LIVN's competition here
DHAI vs ITGR Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, DHAI is priced at $0.00, while ITGR trades at $86.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 31.13. In terms of profitability, DHAI's ROE is +0.22%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, DHAI is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ITGR's competition here
DHAI vs NUVA Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DHAI is priced at $0.00, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DHAI's ROE is +0.22%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DHAI is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NUVA's competition here
DHAI vs ESTA Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, DHAI is priced at $0.00, while ESTA trades at $67.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -38.91. In terms of profitability, DHAI's ROE is +0.22%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, DHAI is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ESTA's competition here
DHAI vs AXGN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AXGN has a market cap of 1.9B. Regarding current trading prices, DHAI is priced at $0.00, while AXGN trades at $37.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is -109.50. In terms of profitability, DHAI's ROE is +0.22%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, DHAI is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AXGN's competition here
DHAI vs AORT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AORT has a market cap of 1.9B. Regarding current trading prices, DHAI is priced at $0.00, while AORT trades at $38.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 184.76. In terms of profitability, DHAI's ROE is +0.22%, compared to AORT's ROE of +0.02%. Regarding short-term risk, DHAI is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AORT's competition here
DHAI vs ATEC Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, DHAI is priced at $0.00, while ATEC trades at $11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -12.03. In terms of profitability, DHAI's ROE is +0.22%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, DHAI is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ATEC's competition here
DHAI vs AHCO Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AHCO has a market cap of 1.7B. Regarding current trading prices, DHAI is priced at $0.00, while AHCO trades at $12.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is -24.37. In terms of profitability, DHAI's ROE is +0.22%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, DHAI is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AHCO's competition here
DHAI vs INSP Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, DHAI is priced at $0.00, while INSP trades at $56.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 11.65. In terms of profitability, DHAI's ROE is +0.22%, compared to INSP's ROE of +0.21%. Regarding short-term risk, DHAI is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INSP's competition here
DHAI vs UFPT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, UFPT has a market cap of 1.6B. Regarding current trading prices, DHAI is priced at $0.00, while UFPT trades at $203.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 23.01. In terms of profitability, DHAI's ROE is +0.22%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, DHAI is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check UFPT's competition here
DHAI vs TNDM Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, DHAI is priced at $0.00, while TNDM trades at $20.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -6.99. In terms of profitability, DHAI's ROE is +0.22%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, DHAI is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TNDM's competition here
DHAI vs PRCT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, DHAI is priced at $0.00, while PRCT trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -14.62. In terms of profitability, DHAI's ROE is +0.22%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, DHAI is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PRCT's competition here
DHAI vs PMI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PMI has a market cap of 1.4B. Regarding current trading prices, DHAI is priced at $0.00, while PMI trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PMI's P/E ratio is -1.21. In terms of profitability, DHAI's ROE is +0.22%, compared to PMI's ROE of +2.17%. Regarding short-term risk, DHAI is more volatile compared to PMI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PMI's competition here
DHAI vs BFLY Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, DHAI is priced at $0.00, while BFLY trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -17.73. In terms of profitability, DHAI's ROE is +0.22%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BFLY's competition here
DHAI vs HSKA Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DHAI is priced at $0.00, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DHAI's ROE is +0.22%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DHAI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check HSKA's competition here
DHAI vs CNMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while CNMD trades at $40.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 26.29. In terms of profitability, DHAI's ROE is +0.22%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, DHAI is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CNMD's competition here
DHAI vs IRMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, DHAI is priced at $0.00, while IRMD trades at $91.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 53.10. In terms of profitability, DHAI's ROE is +0.22%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, DHAI is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IRMD's competition here
DHAI vs AVNS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AVNS has a market cap of 1.1B. Regarding current trading prices, DHAI is priced at $0.00, while AVNS trades at $24.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is -15.69. In terms of profitability, DHAI's ROE is +0.22%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, DHAI is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AVNS's competition here
DHAI vs SILK Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DHAI is priced at $0.00, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, DHAI's ROE is +0.22%, compared to SILK's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SILK's competition here
DHAI vs FNA Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DHAI is priced at $0.00, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, DHAI's ROE is +0.22%, compared to FNA's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check FNA's competition here
DHAI vs SSII Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SSII has a market cap of 970.6M. Regarding current trading prices, DHAI is priced at $0.00, while SSII trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -80.83. In terms of profitability, DHAI's ROE is +0.22%, compared to SSII's ROE of -0.30%. Regarding short-term risk, DHAI is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SSII's competition here
DHAI vs LMRI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, LMRI has a market cap of 927.5M. Regarding current trading prices, DHAI is priced at $0.00, while LMRI trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -14.62. In terms of profitability, DHAI's ROE is +0.22%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, DHAI is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LMRI's competition here
DHAI vs INMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, INMD has a market cap of 923.8M. Regarding current trading prices, DHAI is priced at $0.00, while INMD trades at $14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 10.20. In terms of profitability, DHAI's ROE is +0.22%, compared to INMD's ROE of +0.15%. Regarding short-term risk, DHAI is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INMD's competition here
DHAI vs IART Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, IART has a market cap of 869.8M. Regarding current trading prices, DHAI is priced at $0.00, while IART trades at $11.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas IART's P/E ratio is -1.66. In terms of profitability, DHAI's ROE is +0.22%, compared to IART's ROE of -0.44%. Regarding short-term risk, DHAI is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check IART's competition here
DHAI vs CSII Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DHAI is priced at $0.00, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, DHAI's ROE is +0.22%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DHAI is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CSII's competition here
DHAI vs CBLL Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CBLL has a market cap of 795.4M. Regarding current trading prices, DHAI is priced at $0.00, while CBLL trades at $21.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -14.47. In terms of profitability, DHAI's ROE is +0.22%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, DHAI is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CBLL's competition here
DHAI vs CRY Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, DHAI is priced at $0.00, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CRY's P/E ratio is 425.71. In terms of profitability, DHAI's ROE is +0.22%, compared to CRY's ROE of +0.02%. Regarding short-term risk, DHAI is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CRY's competition here
DHAI vs BVS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BVS has a market cap of 692.5M. Regarding current trading prices, DHAI is priced at $0.00, while BVS trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 31.15. In terms of profitability, DHAI's ROE is +0.22%, compared to BVS's ROE of +0.14%. Regarding short-term risk, DHAI is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BVS's competition here
DHAI vs SIBN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SIBN has a market cap of 632.4M. Regarding current trading prices, DHAI is priced at $0.00, while SIBN trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -32.55. In terms of profitability, DHAI's ROE is +0.22%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, DHAI is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SIBN's competition here
DHAI vs BWAY Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BWAY has a market cap of 615M. Regarding current trading prices, DHAI is priced at $0.00, while BWAY trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BWAY's P/E ratio is 87.11. In terms of profitability, DHAI's ROE is +0.22%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BWAY's competition here
DHAI vs SRDX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, DHAI is priced at $0.00, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, DHAI's ROE is +0.22%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, DHAI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SRDX's competition here
DHAI vs CTKB Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CTKB has a market cap of 587.5M. Regarding current trading prices, DHAI is priced at $0.00, while CTKB trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -8.79. In terms of profitability, DHAI's ROE is +0.22%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, DHAI is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CTKB's competition here
DHAI vs TCMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, TCMD has a market cap of 580.6M. Regarding current trading prices, DHAI is priced at $0.00, while TCMD trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 31.12. In terms of profitability, DHAI's ROE is +0.22%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, DHAI is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TCMD's competition here
DHAI vs APEN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DHAI is priced at $0.00, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, DHAI's ROE is +0.22%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DHAI is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check APEN's competition here
DHAI vs NPCE Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, NPCE has a market cap of 556.5M. Regarding current trading prices, DHAI is priced at $0.00, while NPCE trades at $16.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -25.05. In terms of profitability, DHAI's ROE is +0.22%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, DHAI is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NPCE's competition here
DHAI vs ZIMV Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, DHAI is priced at $0.00, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, DHAI's ROE is +0.22%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, DHAI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ZIMV's competition here
DHAI vs PACB Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PACB has a market cap of 525.5M. Regarding current trading prices, DHAI is priced at $0.00, while PACB trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -0.96. In terms of profitability, DHAI's ROE is +0.22%, compared to PACB's ROE of -11.23%. Regarding short-term risk, DHAI is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PACB's competition here
DHAI vs OFIX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, OFIX has a market cap of 507.8M. Regarding current trading prices, DHAI is priced at $0.00, while OFIX trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -5.43. In terms of profitability, DHAI's ROE is +0.22%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, DHAI is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check OFIX's competition here
DHAI vs VREX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, VREX has a market cap of 501.8M. Regarding current trading prices, DHAI is priced at $0.00, while VREX trades at $12.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas VREX's P/E ratio is -7.30. In terms of profitability, DHAI's ROE is +0.22%, compared to VREX's ROE of -0.14%. Regarding short-term risk, DHAI is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check VREX's competition here
DHAI vs KIDS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, KIDS has a market cap of 420.9M. Regarding current trading prices, DHAI is priced at $0.00, while KIDS trades at $16.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -9.85. In terms of profitability, DHAI's ROE is +0.22%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, DHAI is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check KIDS's competition here
DHAI vs CERS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CERS has a market cap of 394M. Regarding current trading prices, DHAI is priced at $0.00, while CERS trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -25.62. In terms of profitability, DHAI's ROE is +0.22%, compared to CERS's ROE of -0.26%. Regarding short-term risk, DHAI is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CERS's competition here
DHAI vs DCTH Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, DCTH has a market cap of 378M. Regarding current trading prices, DHAI is priced at $0.00, while DCTH trades at $10.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 155.43. In terms of profitability, DHAI's ROE is +0.22%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, DHAI is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check DCTH's competition here
DHAI vs LAB Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, LAB has a market cap of 377.4M. Regarding current trading prices, DHAI is priced at $0.00, while LAB trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas LAB's P/E ratio is -6.45. In terms of profitability, DHAI's ROE is +0.22%, compared to LAB's ROE of -0.18%. Regarding short-term risk, DHAI is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LAB's competition here
DHAI vs VMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, VMD has a market cap of 372.9M. Regarding current trading prices, DHAI is priced at $0.00, while VMD trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 26.11. In terms of profitability, DHAI's ROE is +0.22%, compared to VMD's ROE of +0.11%. Regarding short-term risk, DHAI is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check VMD's competition here
DHAI vs CATX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CATX has a market cap of 335.2M. Regarding current trading prices, DHAI is priced at $0.00, while CATX trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -3.23. In terms of profitability, DHAI's ROE is +0.22%, compared to CATX's ROE of -0.41%. Regarding short-term risk, DHAI is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CATX's competition here
DHAI vs CLPT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CLPT has a market cap of 331M. Regarding current trading prices, DHAI is priced at $0.00, while CLPT trades at $11.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -12.40. In terms of profitability, DHAI's ROE is +0.22%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, DHAI is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CLPT's competition here
DHAI vs SMLR Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, DHAI is priced at $0.00, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, DHAI's ROE is +0.22%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, DHAI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SMLR's competition here
DHAI vs RXST Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, RXST has a market cap of 307M. Regarding current trading prices, DHAI is priced at $0.00, while RXST trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -7.83. In terms of profitability, DHAI's ROE is +0.22%, compared to RXST's ROE of -0.14%. Regarding short-term risk, DHAI is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check RXST's competition here
DHAI vs SENS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SENS has a market cap of 287.1M. Regarding current trading prices, DHAI is priced at $0.00, while SENS trades at $6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -4.14. In terms of profitability, DHAI's ROE is +0.22%, compared to SENS's ROE of -1.04%. Regarding short-term risk, DHAI is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SENS's competition here
DHAI vs MASS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, MASS has a market cap of 272.9M. Regarding current trading prices, DHAI is priced at $0.00, while MASS trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas MASS's P/E ratio is -7.85. In terms of profitability, DHAI's ROE is +0.22%, compared to MASS's ROE of +0.13%. Regarding short-term risk, DHAI is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MASS's competition here
DHAI vs MGRM Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, DHAI is priced at $0.00, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -11.11. In terms of profitability, DHAI's ROE is +0.22%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, DHAI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MGRM's competition here
DHAI vs SGHT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SGHT has a market cap of 235.5M. Regarding current trading prices, DHAI is priced at $0.00, while SGHT trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -5.89. In terms of profitability, DHAI's ROE is +0.22%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, DHAI is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SGHT's competition here
DHAI vs ANIK Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ANIK has a market cap of 228.1M. Regarding current trading prices, DHAI is priced at $0.00, while ANIK trades at $15.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ANIK's P/E ratio is -22.60. In terms of profitability, DHAI's ROE is +0.22%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, DHAI is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ANIK's competition here
DHAI vs NVRO Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DHAI is priced at $0.00, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DHAI's ROE is +0.22%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DHAI is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NVRO's competition here
DHAI vs AVR Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, AVR has a market cap of 217.8M. Regarding current trading prices, DHAI is priced at $0.00, while AVR trades at $5.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -2.32. In terms of profitability, DHAI's ROE is +0.22%, compared to AVR's ROE of -5.28%. Regarding short-term risk, DHAI is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check AVR's competition here
DHAI vs PROF Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, PROF has a market cap of 216.4M. Regarding current trading prices, DHAI is priced at $0.00, while PROF trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.07. In terms of profitability, DHAI's ROE is +0.22%, compared to PROF's ROE of -0.80%. Regarding short-term risk, DHAI is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check PROF's competition here
DHAI vs ELMD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, ELMD has a market cap of 211.8M. Regarding current trading prices, DHAI is priced at $0.00, while ELMD trades at $25.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 24.65. In terms of profitability, DHAI's ROE is +0.22%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, DHAI is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check ELMD's competition here
DHAI vs EYES Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, DHAI is priced at $0.00, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas EYES's P/E ratio is N/A. In terms of profitability, DHAI's ROE is +0.22%, compared to EYES's ROE of -3.17%. Regarding short-term risk, DHAI is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EYES's competition here
DHAI vs BSGM Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, DHAI is priced at $0.00, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, DHAI's ROE is +0.22%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, DHAI is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check BSGM's competition here
DHAI vs CVRX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, CVRX has a market cap of 190.5M. Regarding current trading prices, DHAI is priced at $0.00, while CVRX trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas CVRX's P/E ratio is -3.55. In terms of profitability, DHAI's ROE is +0.22%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, DHAI is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check CVRX's competition here
DHAI vs QTI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, QTI has a market cap of 189.9M. Regarding current trading prices, DHAI is priced at $0.00, while QTI trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas QTI's P/E ratio is -3.48. In terms of profitability, DHAI's ROE is +0.22%, compared to QTI's ROE of +3.64%. Regarding short-term risk, DHAI is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check QTI's competition here
DHAI vs INGN Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, INGN has a market cap of 189.3M. Regarding current trading prices, DHAI is priced at $0.00, while INGN trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -8.08. In terms of profitability, DHAI's ROE is +0.22%, compared to INGN's ROE of -0.12%. Regarding short-term risk, DHAI is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check INGN's competition here
DHAI vs MDGS Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, DHAI is priced at $0.00, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, DHAI's ROE is +0.22%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, DHAI is more volatile compared to MDGS. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check MDGS's competition here
DHAI vs TLSI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, TLSI has a market cap of 174.4M. Regarding current trading prices, DHAI is priced at $0.00, while TLSI trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas TLSI's P/E ratio is -2.50. In terms of profitability, DHAI's ROE is +0.22%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, DHAI is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TLSI's competition here
DHAI vs SNWV Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, SNWV has a market cap of 171.4M. Regarding current trading prices, DHAI is priced at $0.00, while SNWV trades at $20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas SNWV's P/E ratio is 48.63. In terms of profitability, DHAI's ROE is +0.22%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, DHAI is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check SNWV's competition here
DHAI vs APYX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, APYX has a market cap of 164.8M. Regarding current trading prices, DHAI is priced at $0.00, while APYX trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas APYX's P/E ratio is -14.59. In terms of profitability, DHAI's ROE is +0.22%, compared to APYX's ROE of -1.18%. Regarding short-term risk, DHAI is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check APYX's competition here
DHAI vs QIPT Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, DHAI is priced at $0.00, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.87. In terms of profitability, DHAI's ROE is +0.22%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, DHAI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check QIPT's competition here
DHAI vs QTRX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, QTRX has a market cap of 154.9M. Regarding current trading prices, DHAI is priced at $0.00, while QTRX trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas QTRX's P/E ratio is -1.31. In terms of profitability, DHAI's ROE is +0.22%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, DHAI is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check QTRX's competition here
DHAI vs NNOX Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, NNOX has a market cap of 150M. Regarding current trading prices, DHAI is priced at $0.00, while NNOX trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas NNOX's P/E ratio is -2.45. In terms of profitability, DHAI's ROE is +0.22%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, DHAI is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check NNOX's competition here
DHAI vs LUCD Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, LUCD has a market cap of 133M. Regarding current trading prices, DHAI is priced at $0.00, while LUCD trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas LUCD's P/E ratio is -1.88. In terms of profitability, DHAI's ROE is +0.22%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, DHAI is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check LUCD's competition here
DHAI vs TMCI Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, TMCI has a market cap of 127.2M. Regarding current trading prices, DHAI is priced at $0.00, while TMCI trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas TMCI's P/E ratio is -2.12. In terms of profitability, DHAI's ROE is +0.22%, compared to TMCI's ROE of -0.62%. Regarding short-term risk, DHAI is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check TMCI's competition here
DHAI vs EDAP Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, EDAP has a market cap of 125.9M. Regarding current trading prices, DHAI is priced at $0.00, while EDAP trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas EDAP's P/E ratio is -4.31. In terms of profitability, DHAI's ROE is +0.22%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, DHAI is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check EDAP's competition here
DHAI vs RCEL Comparison April 2026
DHAI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DHAI stands at 2.1K. In comparison, RCEL has a market cap of 124.2M. Regarding current trading prices, DHAI is priced at $0.00, while RCEL trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DHAI currently has a P/E ratio of N/A, whereas RCEL's P/E ratio is -2.87. In terms of profitability, DHAI's ROE is +0.22%, compared to RCEL's ROE of +4.77%. Regarding short-term risk, DHAI is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for DHAI.Check RCEL's competition here